Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus

Vivek Sabharwal, Eugene Ramsay, Raisa Martinez, Rachel Shumate, Fawad Khan, Hina Dave, Ifeanyi Iwuchukwu, Harold McGrade

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Retrospective analysis was conducted of patients with SRSE who were treated simultaneously with propofol and ketamine. Sixty-seven patients were identified from 2012 to 2015, and outcomes documented were resolution and mortality. The duration of combined ketamine and propofol use ranged from 1 to 28 days (mean - 3.6 days). Infusion rates ranged up to 145 and 175 mcg/kg/min. Vasopressors were used in 53 patients (79%), and were given within the first 5 days of the ICU admission in 48 (91%) patients. The overall SRSE resolution rate was 91%, and the overall mortality including patients with anoxic brain injury was 39%. Of the 13 patients with SRSE as a result of anoxic brain injury, SRSE was controlled in 5 (56%). The primary determinant of mortality was family withdrawing care related to the presence of severe medical/neurological diseases.

Original languageEnglish (US)
Pages (from-to)264-266
Number of pages3
JournalEpilepsy and Behavior
Volume52
DOIs
StatePublished - Nov 1 2015

Fingerprint

Status Epilepticus
Ketamine
Propofol
Brain Injuries
Mortality
Therapeutics
Withholding Treatment

Keywords

  • Anesthetic agents
  • Ketamine
  • Mortality
  • Propofol
  • Seizure control
  • Super-refractory status epilepticus
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Behavioral Neuroscience
  • Neurology
  • Medicine(all)

Cite this

Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus. / Sabharwal, Vivek; Ramsay, Eugene; Martinez, Raisa; Shumate, Rachel; Khan, Fawad; Dave, Hina; Iwuchukwu, Ifeanyi; McGrade, Harold.

In: Epilepsy and Behavior, Vol. 52, 01.11.2015, p. 264-266.

Research output: Contribution to journalArticle

Sabharwal, V, Ramsay, E, Martinez, R, Shumate, R, Khan, F, Dave, H, Iwuchukwu, I & McGrade, H 2015, 'Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus', Epilepsy and Behavior, vol. 52, pp. 264-266. https://doi.org/10.1016/j.yebeh.2015.07.040
Sabharwal, Vivek ; Ramsay, Eugene ; Martinez, Raisa ; Shumate, Rachel ; Khan, Fawad ; Dave, Hina ; Iwuchukwu, Ifeanyi ; McGrade, Harold. / Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus. In: Epilepsy and Behavior. 2015 ; Vol. 52. pp. 264-266.
@article{df2680da8aad40a190fa6486e099133b,
title = "Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus",
abstract = "Retrospective analysis was conducted of patients with SRSE who were treated simultaneously with propofol and ketamine. Sixty-seven patients were identified from 2012 to 2015, and outcomes documented were resolution and mortality. The duration of combined ketamine and propofol use ranged from 1 to 28 days (mean - 3.6 days). Infusion rates ranged up to 145 and 175 mcg/kg/min. Vasopressors were used in 53 patients (79{\%}), and were given within the first 5 days of the ICU admission in 48 (91{\%}) patients. The overall SRSE resolution rate was 91{\%}, and the overall mortality including patients with anoxic brain injury was 39{\%}. Of the 13 patients with SRSE as a result of anoxic brain injury, SRSE was controlled in 5 (56{\%}). The primary determinant of mortality was family withdrawing care related to the presence of severe medical/neurological diseases.",
keywords = "Anesthetic agents, Ketamine, Mortality, Propofol, Seizure control, Super-refractory status epilepticus, Treatment",
author = "Vivek Sabharwal and Eugene Ramsay and Raisa Martinez and Rachel Shumate and Fawad Khan and Hina Dave and Ifeanyi Iwuchukwu and Harold McGrade",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.yebeh.2015.07.040",
language = "English (US)",
volume = "52",
pages = "264--266",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus

AU - Sabharwal, Vivek

AU - Ramsay, Eugene

AU - Martinez, Raisa

AU - Shumate, Rachel

AU - Khan, Fawad

AU - Dave, Hina

AU - Iwuchukwu, Ifeanyi

AU - McGrade, Harold

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Retrospective analysis was conducted of patients with SRSE who were treated simultaneously with propofol and ketamine. Sixty-seven patients were identified from 2012 to 2015, and outcomes documented were resolution and mortality. The duration of combined ketamine and propofol use ranged from 1 to 28 days (mean - 3.6 days). Infusion rates ranged up to 145 and 175 mcg/kg/min. Vasopressors were used in 53 patients (79%), and were given within the first 5 days of the ICU admission in 48 (91%) patients. The overall SRSE resolution rate was 91%, and the overall mortality including patients with anoxic brain injury was 39%. Of the 13 patients with SRSE as a result of anoxic brain injury, SRSE was controlled in 5 (56%). The primary determinant of mortality was family withdrawing care related to the presence of severe medical/neurological diseases.

AB - Retrospective analysis was conducted of patients with SRSE who were treated simultaneously with propofol and ketamine. Sixty-seven patients were identified from 2012 to 2015, and outcomes documented were resolution and mortality. The duration of combined ketamine and propofol use ranged from 1 to 28 days (mean - 3.6 days). Infusion rates ranged up to 145 and 175 mcg/kg/min. Vasopressors were used in 53 patients (79%), and were given within the first 5 days of the ICU admission in 48 (91%) patients. The overall SRSE resolution rate was 91%, and the overall mortality including patients with anoxic brain injury was 39%. Of the 13 patients with SRSE as a result of anoxic brain injury, SRSE was controlled in 5 (56%). The primary determinant of mortality was family withdrawing care related to the presence of severe medical/neurological diseases.

KW - Anesthetic agents

KW - Ketamine

KW - Mortality

KW - Propofol

KW - Seizure control

KW - Super-refractory status epilepticus

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84945551160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945551160&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2015.07.040

DO - 10.1016/j.yebeh.2015.07.040

M3 - Article

C2 - 26523340

AN - SCOPUS:84945551160

VL - 52

SP - 264

EP - 266

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

ER -